Citius Pharmaceuticals Inc. (CTXR) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Contrasting side by side

We are comparing Citius Pharmaceuticals Inc. (NASDAQ:CTXR) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Citius Pharmaceuticals Inc. N/A 0.00 12.54M -1.46 0.00
ANI Pharmaceuticals Inc. 191.74M 3.45 N/A 1.18 46.66

Table 1 demonstrates Citius Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Citius Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Citius Pharmaceuticals Inc. 0.00% -54.8% -49.6%
ANI Pharmaceuticals Inc. 0.00% 0.2% 0.1%

Liquidity

1.3 and 1.3 are the respective Current Ratio and a Quick Ratio of Citius Pharmaceuticals Inc. Its rival ANI Pharmaceuticals Inc.’s Current and Quick Ratios are 3.3 and 2.5 respectively. ANI Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Citius Pharmaceuticals Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Citius Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Citius Pharmaceuticals Inc. 0 0 0 0.00
ANI Pharmaceuticals Inc. 0 0 1 3.00

On the other hand, ANI Pharmaceuticals Inc.’s potential upside is 25.31% and its average price target is $70.

Institutional and Insider Ownership

Citius Pharmaceuticals Inc. and ANI Pharmaceuticals Inc. has shares held by institutional investors as follows: 1.6% and 84.7%. 50.8% are Citius Pharmaceuticals Inc.’s share held by insiders. Insiders Competitively, held 0.4% of ANI Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Citius Pharmaceuticals Inc. -6.84% -22.7% -23.57% -59.36% -77.8% -71.32%
ANI Pharmaceuticals Inc. -1.21% -0.63% -0.62% -17.28% -18.38% -14.79%

For the past year Citius Pharmaceuticals Inc. was more bearish than ANI Pharmaceuticals Inc.

Summary

On 10 of the 10 factors ANI Pharmaceuticals Inc. beats Citius Pharmaceuticals Inc.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.